$OKYO

OKYO Pharma (Nasdaq: OKYO) has enrolled the first patients in its Phase 3 NEPTUNE trial for urcosimod, a potential treatment for neuropathic corneal pain (NCP). The trial, led by Dr. Melissa Toyos, aims to evaluate urcosimod's efficacy in reducing ocular pain and improving quality of life. NCP currently lacks FDA-approved treatments, representing a significant unmet medical need.

OKYO Pharma Limited (NASDAQ:OKYO) said its Chief Scientific Officer Raj Patil bought 3,363 ordinary shares at $1.49 each on Monday, raising his holdings to 20,030 shares. OKYO is a clinical-stage biopharma developing urcosimod for neuropathic corneal pain and plans to start a global Phase 3 trial in the second half of 2024.

OKYO Pharma (Nasdaq: OKYO) filed a Form 6-K saying its Chief Scientific Officer Raj Patil bought 3,363 ordinary shares on Nasdaq at $1.49 each, raising his total to 20,030 shares. The company also said it plans to start a global Phase 3 pivotal trial for neuropathic corneal pain in the second half of 2026, enrolling about 111 patients to test a single-dose urcosimod regimen.

OKYO Pharma (Nasdaq: OKYO) said it will participate in the BTIG Biotechnology Conference 2026 on July 28-29, 2026 with CEO Robert J. Dempsey, CFO Keeren Shah, and CMO Flavio Mantelli. According to the company, it plans to start a global Phase 3 pivotal trial in the second half of the year, enrolling about 111 patients to test urcosimod for neuropathic corneal pain.

OKYO Pharma Limited (Nasdaq: OKYO) said its Chairman, Gabriele Cerrone, via Panetta Partners Ltd, bought 25,000 ordinary shares at $1.40 each. The purchase raises his total to 10,851,416 shares, or 20.51% of issued capital. OKYO is clinical-stage for neuropathic corneal pain and plans a Phase 3 trial in 2H 2026.

US stocks finished mixed as an early rally faded. The Dow fell 307 points, or 0.6%, to 51,839, the S&P 500 slipped 0.2% to 7,443, and the Nasdaq edged down 0.05% to 25,508. Investors trimmed semiconductors ahead of Big Tech earnings, including Alphabet and Tesla, while oil prices stayed volatile above $90.

OKYO Pharma (NASDAQ:OKYO) filed its FY ended March 31, 2026 Form 20-F with the SEC and reported cash and cash equivalents of about $20.6M. The company said it raised about $25M in the fiscal year, including a Feb 2026 public offering with about $22M gross proceeds. OKYO plans to start its NEPTUNE Phase 3 urcosimod trial in H2 2026, enrolling about 111 patients in the US and Europe.

OKYO Pharma (NASDAQ:OKYO) said it received positive feedback from a US FDA Type D meeting for urcosimod, giving regulatory clarity for a global Phase 3 pivotal trial in neuropathic corneal pain. The company plans a single-dose Phase 3 study, the Neptune trial, enrolling about 111 patients with 0.05% urcosimod vs placebo (2:1). It is finalizing about 14 sites in the US and Europe and may seek Breakthrough Therapy designation.

OKYO Pharma said the FDA provided positive feedback in a Type D meeting for its investigational drug urcosimod for neuropathic corneal pain. The FDA endorsed a single-dose Phase 3 design and said a potential single-trial registration pathway could be considered if results support it. The NEPTUNE Phase 3 trial will enroll about 111 patients in the US and Europe.

OKYO Pharma said it has cleared a key FDA milestone and is moving toward a Phase 3 trial for neuropathic corneal pain, according to the company. The update is aimed at advancing its clinical development timeline for the treatment, which may be relevant to investors tracking biotech regulatory progress.